'My number one idea is accumulating the ultra-high quality CSL' shares

Bell Potter says enough is enough, it's time to buy this giant's shares.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Recent months have not been kind to CSL Limited (ASX: CSL) shares.

The biotherapeutics giant's shares have fallen heavily since June and one leading broker believes that they could have finally bottomed.

In fact, Charlie Aitken from Bell Potter thinks "the falling knife is sticking in the valuation floor and it's time to pick it up."

Why now is the time to buy CSL shares

According to a note out of the broker, Aitken highlights that CSL shares are trading on their "lowest relative PE premium to the market since 2017."

In light of this, the analyst feels it is "time to start nibbling in CSL which remains Australia's highest quality global industrial business." Especially with its chair, Dr Brian McNamee, recently reiterating that its intention is to be and remain a growth company for a long time to come.

It is because of this, that Aitken has named the company as his top pick for the month. He said:

My number one idea is accumulating the ultra-high quality CSL. […] McNamee's comments, combined with the reiteration of guidance last week, and arguably peak hysteria on weight loss drugs and some questioning articles in the financial press about CSL's future, all combine with the lowest relative valuation in 6 years to get my attention. I think it's time to start accumulating CSL.

The team at Citi agrees. It has a buy rating and a $325 price target on CSL's shares, which implies a potential upside of approximately 30%.

It recently highlighted that "CSL is trading on a PE FY25 of ~22x, a 6x discount to historical average." The broker also believes that "CSL is winning share [in the United States flu vaccine market] despite the lower vaccination rate."

Overall, quality of this standard doesn't go on sale very often and these brokers are urging investors to take advantage.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »